A new publication on carbetocin appeared in the journal Cureus, dated August 1, 2026. The article is titled "Replacing Routine Oxytocin Infusion With Single-Dose Carbetocin at Elective Caesarean Section: A Service Improvement Evaluation of Postpartum Haemorrhage Outcomes."
The publication is listed as a service improvement evaluation focused on postpartum haemorrhage outcomes in the context of elective caesarean section. No specific findings or results from the evaluation are provided in the available event data.
Carbetocin remains classified as unapproved for research use according to the regulatory status associated with this entry. This brief reports only the existence and title of the publication and does not describe or infer any study outcomes, efficacy, or safety conclusions.
Readers interested in learning more about this evaluation can consult the original article in Cureus for full methodology and results. For general background on carbetocin, see the compound overview linked with this brief.